Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry aims to map biliary tract cancers for future breakthroughs

NCT ID NCT04896931

Knowledge-focused Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed registry study gathered information from 159 people with biliary tract cancers, including gallbladder cancer. The goal was to create a detailed database of patient experiences, treatments, and quality of life to help guide future research. No new drug or treatment was tested in this study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

159 people

The number who actually took part.

Started

Jul 2022

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Permanent, prospective, multicenter registry including all kind of oncological therapy lines and procedures, clinical outcome, translational research (biobanking) and QoL for all types of biliary tract cancers.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Known biliary-tract cancer including intrahepatic-, extrahepatic- and gallbladder carcinomas * age ≥18 years * signed informed consent form * planned for (or recently started - i.e. within the last 21 days)) neoadjuvant, adjuvant or 1st line therapy Exclusion Criteria: * Patients who are unable to consent because they do not understand the nature, significance and implications of the registry and therefore cannot form a rational intention * Patient under 18 years of age * Patient's inability to complete QoL questionnaire or answer the questions. * Second-line or further palliative therapies if the patient's first-line therapy was not documented within the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract cancer Neoadjuvant, adjuvant and 1ST line

Contacts and locations

Locations

  • Ambulantes Zentrum für Hämatologie und Onkologie

    Cottbus, Brandenburg, 03046, Germany

  • Charité - Universitätsmedizin Berlin

    Berlin, 10117, Germany

  • Donau-Isar-Klinikum Deggendorf

    Deggendorf, Bavaria, 94469, Germany

  • Elblandklinikum Riesa

    Riesa, Saxony, 01589, Germany

  • Gemeinschaftspraxis für Onkologie und Hämatologie

    Erfurt, Thuringia, 99085, Germany

  • HELIOS Klinikum Bad Saarow

    Bad Saarow, Brandenburg, 15526, Germany

  • Helios Amper-Klinikum Dachau

    Dachau, Bavaria, 85221, Germany

  • Klinikum Lippe Lemgo

    Lemgo, North Rhine-Westphalia, 32657, Germany

  • Klinikum Oldenburg

    Oldenburg, Lower Saxony, 26133, Germany

  • Klinikum St. Marien Amberg

    Amberg, Bavaria, 92224, Germany

  • Klinikum Südstadt Rostock

    Rostock, Mecklenburg-Vorpommern, 18059, Germany

  • Krankenhaus Maria-Hilf Krefeld

    Krefeld, North Rhine-Westphalia, 47805, Germany

  • Krankenhaus Nordwest GmbH

    Frankfurt, 60488, Germany

  • LMU Klinikum Campus Großhadern

    München, Bavaria, 81377, Germany

  • Medius Klinik Ostfildern-Ruit

    Ostfildern, Baden-Wurttemberg, 73760, Germany

  • Onkologische Schwerpunktpraxis

    Naunhof, Saxony, 04683, Germany

  • Onkologische Schwerpunktpraxis Freital

    Freital, Saxony, 01705, Germany

  • Onkologische Schwerpunktpraxis Speyer

    Speyer, Rhineland-Palatinate, 67346, Germany

  • Onkozentrum Dresden

    Dresden, Saxony, 01127, Germany

  • St. Bernward Krankenhaus Hildesheim

    Hildesheim, Lower Saxony, 31134, Germany

  • Universitäres Krebszentrum Universitätsklinikum Leipzig (UCCL)

    Leipzig, Saxony, 04103, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, 49106, Germany

  • Universitätsklinikum Gießen

    Giessen, Hesse, 35392, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, 97080, Germany

  • ÜBAG-Medizinisches Versorgungszentrum. Dr. Vehling-Kaiser GmbH

    Landshut, Bavaria, 84036, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.